$0.05—Stale · unknown old
NASDAQ • Last print unknown ago
$0.05—Stale · unknown old
Clarus Therapeutics Holdings, Inc. focuses on the development of therapies for men with testosterone deficiency, particularly its lead product, Jatenzo, which is an oral testosterone replacement therapy. The company operates primarily in the U.S. market, leveraging its unique formulation to differentiate itself from traditional injectable therapies.
Clarus generates revenue primarily through the sale of Jatenzo, which is marketed as a convenient oral alternative to injectable testosterone therapies. The company benefits from a high gross margin of 80.5%, indicating strong pricing power and a favorable cost structure due to its proprietary formulation.
Regulatory approvals for new formulations or indications of Jatenzo
Market penetration rates of Jatenzo in the testosterone replacement therapy market
Partnerships or collaborations that enhance distribution capabilities
Changes in reimbursement policies affecting testosterone therapies
Regulatory changes affecting drug approval processes
Technological advancements in competing therapies
Emergence of generic competitors to Jatenzo
Market entry of new therapies with superior efficacy or safety profiles
High operating losses leading to potential liquidity issues
Dependence on external funding for R&D and operational sustainability
moderate - The demand for testosterone replacement therapies can be influenced by overall healthcare spending, which is correlated with GDP growth.
Interest rates affect Clarus's cost of capital and financing options, which could impact its ability to fund R&D and operational expenses.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on external debt financing.
growth - Investors seeking exposure to innovative therapies in the healthcare sector.
high - The stock has shown significant volatility, particularly with a 1-year return of -96.1%.